Sensei Biotherapeutics (NASDAQ:FTH) CFO Acquires $224,842.80 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 9,230 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average cost of $24.36 per share, for a total transaction of $224,842.80. Following the completion of the acquisition, the chief financial officer directly owned 17,413 shares of the company’s stock, valued at $424,180.68. This trade represents a 112.79% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sensei Biotherapeutics Stock Down 7.3%

NASDAQ FTH opened at $22.87 on Friday. Sensei Biotherapeutics, Inc. has a one year low of $6.32 and a one year high of $36.76. The stock has a market capitalization of $30.69 million, a PE ratio of -0.16 and a beta of -0.25.

Analysts Set New Price Targets

Several research firms have recently commented on FTH. Robert W. Baird assumed coverage on Sensei Biotherapeutics in a report on Friday. They set an “outperform” rating and a $57.00 target price for the company. Weiss Ratings started coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 price objective for the company. Finally, BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average target price of $58.50.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.